Search PubMed⌕ Search

Biomedical subjects

A Planes

Publications and source records attributed to A Planes.

At least 55 records · Page 3Linked to original sources
PubMed1992

[Multi-resistant strains of Salmonella typhi in Spain].

Most Salmonella typhi isolated in Spain are susceptible to antibiotics commonly used in its treatment as chloramphenicol, ampicillin and cotrimoxazole. Three multiresistant strains have been isolated from different patients the last two years. Two phage type M1, biotype xylose tetrationate + strains were isolated from blood of two patients in Bembibre (León). One phage type E1a biotype xylose + tetrationate reductase + strain was isolated from blood and faeces of one patient in Barcelona. All strains harboured a 79 Mdal plasmid responsible for multiresistance, chloramphenicol acetyl transferase production and conjugative.

Adolescent↗
PubMed1990

[Infectious endocarditis in drug addicts: a study of 71 cases].

Infective endocarditis (IE) is a severe and relatively common condition in parenteral drug abusers (PDA). Seventy-one IE episodes in 59 PDAs admitted to the Hospital General Vall d'Hebron from August 1978 to December 1988 were evaluated. The disease basically involved young males, with a progressively increasing incidence throughout the decade and a higher frequency during August. Fever was a constant symptom, with a duration of less than 10 days before admission in 73% of cases. Staphylococcus aureus was the most common pathogen (85% of episodes). Vegetations were detected by echocardiography in 70% of cases. In 82% of episodes the right side of the heart was involved, particularly the tricuspid valve. The initial chest X-ray film was abnormal in 57.5% of episodes. In 7 patients features of heart failure were present at admission; most had left heart endocarditis. Three patients with left heart endocarditis required surgical therapy. Overall mortality was 13%; it was 6% in patients with only tricuspid involvement and 27% when the left heart was involved.

Adolescent↗
PubMed1990

[Prevention of deep vein thrombosis by enoxaparin after total hip prosthesis].

Once daily dosing of Enoxaparin to prevent deep vein thrombosis (DVT) after total hip replacement has been defined through two double-blind prospective, randomized multicentric trials. A previous prospective study including 228 consecutive patients had determined optimal dose to be 40 mg daily (4000 anti Xa U) begun 12 hours pre-operatively. The first trial (118 patients) compared two modes of administration of the dose of 40 mg--either 40 mg once daily or 20 mg twice daily, every twelve hours. Results were a figure of 6% for total DVT detected by ascending bilateral phlebography, 5% of wound hematoma and did not shown a statistically significant difference between the two modes of administration as regard tolerance. The second trial (237 patients) compared unfractionated calcic Heparin (5000 U.I. every eight hourly begun two hours before surgery) with Enoxaparin, 40 mg/day begun twelve hours before surgery. In the unfractionated Heparin group, we observed 27 total DVT (25%) 20 proximal DVT (12.5%) and one case of non fatal pulmonary embolism. In the Enoxaparin group, we observed 15 total DVT (12.5%), 9 proximal DVT (7.5%) no case pulmonary embolism. Red-cell transfusion requirements and hemoglobin levels on the third post-operative day shown a significant better tolerance in the Enoxaparin group. Theses results are coherent with those observed in the placebo controlled trial of Turpie, Levine, et al (1986). They used a dose of 30 mg twice daily (6000 anti Xa IU) begun 12/24 hours post-operatively, and observed a figure of 12% for total DVT and 4% for proximal DVT. Tolerance was the same than in the placebo group.

Female↗
PubMed1989

The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement.

Studies in experimental animals have demonstrated that there is a relationship between levels of low molecular weight (LMW) heparin and both bleeding and inhibition of thrombosis. The relationship between these outcomes and ex vivo anti-factor Xa levels has been examined in 163 patients undergoing total hip replacement who were given prophylaxis once daily with a LMW heparin (enoxaparine). Fifty patients received 60 mg of enoxaparine and 113 received 40 mg, both regimens being administered subcutaneously once daily. Blood samples for anti-factor Xa levels were collected 12 hours after the injection on the day of surgery and on days 1, 3 and 6, postoperatively. The incidence of wound hematoma was 5.3% when the maximum anti-factor Xa level was less than or equal to 0.2 units per ml, but increased to 24.5% when the anti-factor Xa level exceeded 0.2 units per ml, P = 0.0008. The incidence of postoperative thrombosis was low (6.3%) if the minimum anti-factor Xa level exceeded 0.1 units per ml, but increased to 14.6% when less than or equal to 0.1 units per ml, and to 18.8% if the anti-factor Xa level was less than or equal to 0.05 units per ml. Regression analysis revealed that there was a statistically significant relationship between anti-factor Xa level and wound hematoma, P = 0.002 and anti-factor Xa level and thrombosis, P = 0.03. These findings suggest that when enoxaparine is administered as a once daily subcutaneous injection, the 12 hour anti-factor Xa level should not exceed 0.2 units per ml to minimize bleeding and levels greater than 0.05 units per ml should be obtained to optimize efficacy.

Factor Xa Inhibitors↗
PubMed1988

Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.

A double blind randomized trial comparing subcutaneous enoxaparin (40 mg once daily) with standard unfractionated calcium heparin administered at a dose of 5,000 units every 8 hours in patients undergoing elective hip replacement has been performed. Treatment regimens began 12 hours preoperatively with enoxaparin, 2 hours preoperatively with standard unfractionated calcium heparin, and were continued for 15 days or until discharge. Venography was performed in all patients. Two hundred thirty-seven patients were included in the study: 113 received unfractionated heparin and 124 received enoxaparin. The incidence of proximal deep vein thrombosis was reduced from 18.5% in the unfractionated heparin group to 7.5% in the enoxaparin group (p = 0.014), and the incidence of total deep vein thrombosis was similarly reduced from 25% to 12.5% (p = 0.03). There were two major bleeding episodes and one minor bleed in the enoxaparin group compared to two minor bleeds in the unfractionated heparin group. Patients who received enoxaparin required fewer red blood cell transfusions and had a significantly higher hemoglobin on postoperative days 3 and 4. Thus prophylaxis with enoxaparin, 40 mg once daily, is simple, safe and more effective than standard low dose unfractionated heparin in preventing deep vein thrombosis in patients undergoing elective hip replacement.

Aged↗
PubMed1986

Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement.

UNLABELLED: The effect of Enoxaparin in the prevention of thromboembolism after total hip prosthesis has been controlled by phlebography. 228 consecutives patients were studied with 4 dose regimens: 60 mg once a day, 40 mg once a day, and 30 and 20 mg twice a day. CONCLUSIONS: a total dose of 40 mg once a day or twice a day gives a rate of postoperative thrombosis of 8%.

Aged↗